StockData

Moleculin Biotech vs SELLAS Life Sciences

MBRX and SLS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How MBRX and SLS compare

SELLAS Life Sciences is the larger company, worth 11 times as much as Moleculin Biotech ($1.5B against $139M).

SELLAS Life Sciences scores higher on the StockData Score (7 against 4 for Moleculin Biotech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricMBRXSLS
Size and price
Market cap$139M$1.5B
Share price$7.14$7.47
Change, 1 year−96.9%412%
Change, 5 years−100.0%6.1%
Beta (5Y)−1.160.65
Employees150K13
StockData Score
Total score47 (better)
Valuation score00
Growth score00
Performance score01 (better)
Health score46 (better)
Dividend score00
Valuation
P/B12.0×11.0× (better)
Profitability
Return on equity−524%−39.6% (better)
Return on invested capital–−85609%
Financial health
Debt / equity0.000.00
Current ratio0.9418.83 (better)
Altman Z-score−10.81114.64 (better)
Piotroski F-score34 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions0.05%36.5%
Held by insiders20.2%1.8%
Insider net buying, 12 months–$0
Short interest, % of float0.35%28.8%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.